Faculty

Back to Index
Giridharan Ramsingh, MBBS, MD
Assistant Professor of Medicine
Medicine
NRT 3503 Health Sciences Campus Los Angeles
+1 323 442 8071

Overview

Dr. Ramsingh's laboratory research interests include genetic changes underlying the development of leukemia in patients previously treated with chemotherapy. He is particularly focused on understanding the mechanism of aging in Hematopoietic stem and progenitor cells and its contribution to leukemogensis.

Dr. Ramsingh earned his medical degree from Christian Medical College, and then stayed on to perform his internship and residency. He then completed two fellowships, one in hematology/oncology, and the other in stem cell biology at Washington University School of Medicine.

Awards

American Society of Hematology: Travel Award, 2009

Tower Cancer Foundation: Career Development Award, 2014-2015

National Council for Education Research and Training: Scholarship, 1993-2002

American Society for Blood and Marrow Transplantation: Travel Award, 2010

American Society of Clinical Oncology: Young Investigator Award, 2009-2010

Washington University: Translational Oncology Pilot Grant Award, 2012

STOP Cancer: Career Development Award, 2013-2016

Christian Medical College: Best Outgoing Medical Student, 1999

American Association of Cancer Research: Translational Cancer Medicine Travel Award, 2010

Publications

Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, Lamprecht TL, Shen D, Hundal J, Fulton RS, Heath S, Baty JD, Klco JM, Ding L, Mardis ER, Westervelt P, DiPersio JF, Walter MJ, Graubert TA, Ley TJ, Druley TE, Link DC, Wilson RK. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015 Feb 26; 518(7540):552-5. View in: PubMed

Ramsingh G, Westervelt P, McBride A, Stockerl-Goldstein K, Vij R, Fiala M, Uy G, Cashen A, Dipersio JF, Abboud CN. Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Int J Hematol. 2014 Mar; 99(3):272-8. View in: PubMed

Ramsingh G, Jacoby MA, Shao J, De Jesus Pizzaro RE, Shen D, Trissal M, Getz AH, Ley TJ, Walter MJ, Link DC. Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon. Blood. 2013 Oct 10; 122(15):e44-51. View in: PubMed

Ramsingh G, Koboldt DC, Trissal M, Chiappinelli KB, Wylie T, Koul S, Chang LW, Nagarajan R, Fehniger TA, Goodfellow P, Magrini V, Wilson RK, Ding L, Ley TJ, Mardis ER, Link DC. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood. 2010 Dec 9; 116(24):5316-26. View in: PubMed

Fehniger TA, Wylie T, Germino E, Leong JW, Magrini VJ, Koul S, Keppel CR, Schneider SE, Koboldt DC, Sullivan RP, Heinz ME, Crosby SD, Nagarajan R, Ramsingh G, Link DC, Ley TJ, Mardis ER. Next-generation sequencing identifies the natural killer cell microRNA transcriptome. Genome Res. 2010 Nov; 20(11):1590-604. View in: PubMed

Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer. 2009 Dec 15; 115(24):5734-9. View in: PubMed

Ramsingh G, Mehan P, Morgensztern D, Luo J, Vij R. Prognostic factors influencing survival in solitary plasmacytoma. Br J Haematol. 2009 May; 145(4):540-2. View in: PubMed

Advani AS, Jin T, Ramsingh G, Tiu R, Saber W, Theil K, Sobecks R, Sekeres M, Copelan E, Sungren S, Tripp B, Kalaycio M. Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2008 Aug; 49(8):1560-6. View in: PubMed

Thakkar SG, Fu AZ, Sweetenham JW, Mciver ZA, Mohan SR, Ramsingh G, Advani AS, Sobecks R, Rybicki L, Kalaycio M, Sekeres MA. Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit. Cancer. 2008 May 15; 112(10):2233-40. View in: PubMed

Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol. 2007 Feb; 31(2):233-9. View in: PubMed

Powered bySC CTSI